Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
Company Growth (employees)
Type
Public
HQ
Newton, US
Founded
2001
Size (employees)
23 (est)
Chiasma was founded in 2001 and is headquartered in Newton, US

Key People at Chiasma

Roni Mamluk

Roni Mamluk

CEO
Dana Gelbaum

Dana Gelbaum

VP of BD and Supply Chain
Shoshie Katz

Shoshie Katz

VP of Quality Assurance & Regulatory Affairs
Asi Haviv

Asi Haviv

VP of Clinical Development
Lillian Kuan

Lillian Kuan

Alumni Advisory Committee Board Member

Chiasma Office Locations

Chiasma has offices in Newton, Jerusalem and Auckland,
Newton, US (HQ)
313 831 Beacon St
Jerusalem, IL
10 Hartom Street

Chiasma Data and Metrics

Chiasma Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(61.1 m)

EBIT (FY, 2016)

(61.3 m)

Market capitalization (26-May-2017)

36.5 m

Closing share price (26-May-2017)

1.5

Cash (31-Dec-2016)

37 m
Chiasma's current market capitalization is $36.5 m.
Numbers are in $, USDFY, 2015FY, 2016

R&D expense

19 m31.3 m

Operating expense total

35.4 m61.3 m

EBIT

(35.4 m)(61.3 m)

Pre tax profit

(60.8 m)

Income tax expense

161 k347 k

Net Income

(35.9 m)(61.1 m)
Numbers are in $, USDFY, 2015FY, 2016

Cash

41 m37 m

Inventories

2.3 m2.1 m

Current Assets

151.1 m95.1 m

PP&E

676 k683 k

Total Assets

153.1 m96.8 m

Accounts Payable

157 k1.2 m

Current Liabilities

6.5 m8.4 m

Additional Paid-in Capital

260 m264 m

Retained Earnings

(117.4 m)(178.5 m)

Total Equity

142.8 m85.7 m

Financial Leverage

1.1 x1.1 x
Numbers are in $, USDFY, 2015FY, 2016

Net Income

(35.9 m)(61.1 m)

Depreciation and Amortization

201 k433 k

Accounts Receivable

(215 k)(215 k)

Inventories

(1.7 m)674 k

Accounts Payable

(161 k)1.8 m

Cash From Operating Activities

(33.3 m)(52 m)

Purchases of PP&E

(269 k)(3 m)

Cash From Investing Activities

(109.1 m)49 m

Long-term Borrowings

(11.1 m)

Cash From Financing Activities

143.3 m(1.1 m)

Interest Paid

921 k

Income Taxes Paid

69 k140 k
Y, 2016

Financial Leverage

1.1 x

Chiasma Market Value History

Chiasma Online and Social Media Presence

Chiasma Company Life and Culture

You may also be interested in